Celularity Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M | $14.3M |
| Cost of Revenue | $20.1M | $15.0M | $16.0M | — | — | — |
| Gross Profit | $6.5M | $39.2M | $6.8M | $-1.7M | $11.7M | $9.3M |
| Gross Margin | 24.4% | 72.4% | 29.7% | -9.4% | 54.8% | 65.5% |
| Operating Expenses | ||||||
| Research & Development | $15.0M | $17.4M | $30.5M | $78.4M | $88.4M | $52.7M |
| SG&A Expense | $51.3M | $58.6M | $50.6M | $66.0M | $71.3M | $31.3M |
| Operating Income | $-61.3M | $-38.4M | $-192.3M | $-25.6M | $-109.1M | $-151.9M |
| Operating Margin | -230.9% | -70.7% | -844.4% | -142.4% | -511.2% | -1,064.0% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-91.7M | $-57.9M | $-196.3M | $14.2M | $-100.1M | $-212.9M |
| Income Tax Expense | $3.0K | — | $10.0K | $13.0K | $20.0K | $-4.7M |
| Net Income | $-91.7M | $-57.9M | $-196.3M | $14.2M | $-100.1M | $-208.2M |
| Net Margin | -345.4% | -106.8% | -862.0% | 79.0% | -469.3% | -1,458.4% |
| EPS (Basic) | $-3.59 | $-2.64 | $-11.02 | $1.01 | $-1.49 | $-11.31 |
| EPS (Diluted) | $-3.59 | $-2.64 | $-11.02 | $0.95 | $-1.49 | $-11.31 |
| Shares Outstanding (Basic) | 25.6M | 21.9M | 17.8M | 14.0M | 67.1M | 18.5M |
| Shares Outstanding (Diluted) | 25.6M | 21.9M | 17.8M | 15.0M | 67.1M | 18.5M |
| Dividends Per Share | — | — | — | — | — | — |